Daniel Bollag, Ph.D., is a regulatory consultant for HiberCell.  Dan has spent over 30 years in the biotech/pharmaceutical industry and has been a regulatory consultant since 2020.

Dan has extensive experience leading regulatory and quality teams, having served as Senior Vice President of Regulatory Affairs & Quality at both Ariad Pharmaceuticals and Ocular Therapeutix.  In his tenures, he oversaw the approval of the ocular insert Dextenza for ocular inflammation and pain following ophthalmic surgery and the accelerated approvals of Iclusig and Alunbrig for chronic myeloid leukemia and ALK-positive metastatic non-small cell lung cancer, respectively.  Earlier in his career, Dan held senior regulatory and project management roles at Genzyme, Sanofi, Bristol-Myers Squibb and Merck.

Dan received his PhD in biochemistry from Cornell University.